Cellectar Biosciences Q2 EPS $(0.57) Misses $(0.48) Estimate
Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.48) by 18.75 percent. This is a 83.19 percent increase over losses of $(3.39) per
Cellectar lost more money per share than experts thought it would—like spending $0.57 when people expected $0.48. But the good news is they're losing way less money than they did a year ago, which shows they're getting better at managing costs.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.